Insulet Announces $85 Million Deal with Cannacord Genuity
Insulet, a diabetes management company based in Bedford, Massachusetts, announced that it entered a new deal with Canaccord Genuity. The new deal will give Canaccord Genuity an $85 million stake in Insulet’s common stock.
we cannot guarantee an optimized experience, including access to certain video content.
For more information, please see our Privacy & Cookies Policy.